Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory Midh1 Acute Myeloid Leukemia

Stephane De Botton,Karen Yee, Christian Recher,Andrew H. Wei,Pau Montesinos,David Taussig,Arnaud Pigneux,Thorsten Braun,Antonio Curti,Jordi Esteve,Carolyn Grove,Brian A. Jonas,Asim Khwaja,Olivier Legrand,Pierre Peterlin,Montserrat Arnan Sangerman,William G. Blum,Daniela Cilloni,Devendra Hiwase,Joseph G. Jurcic, Jurgen Krauter, Xavier Thomas, Justin Watts, Jay Yang, Zihao Xin, Alex Sedkov, Sylvie Guichard, Jennifer Sweeney, Christophe Marzac, Jorge E. Cortes, Pierre Fenaux

Blood（2021）

Cited 3|Views17

No score

Abstract

Background: Olutasidenib is a potent, selective, oral, small molecule inhibitor of mutant IDH1 (mIDH1). Olutasidenib has previously shown clinical activity in high-risk AML patients (pts) in a Phase 1 clinical trial (Watts, Blood 2019). The planned interim analysis of an ongoing Phase 2 clinical trial (NCT02719574) in R/R mIDH1 AML pts receiving single-agent olutasidenib 150 mg twice-daily showed an overall response rate (ORR) of 46%, including 33% of pts with CR/CRh (de Botton et al., ASCO/EHA 2021). Here we present data analysis on the mutational characteristics of these pts and the relationship between mutations and clinical response.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined